Full text

Turn on search term navigation

© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) remains a clinical challenge for up to 80% of breast cancer survivors. In an open-label study, participants underwent three interventions: standard care (duloxetine) for 1 month (Phase 1), oral cannabidiol (CBD) for 2 months (Phase 2), and CBD plus multi-modal exercise (MME) for another 2 months (Phase 3). Clinical outcomes and gut microbiota composition were assessed at baseline and after each phase. We present the case of a 52-year-old female with a history of triple-negative breast cancer in remission for over five years presenting with CIPN. She showed decreased monocyte counts, c-reactive protein, and systemic inflammatory index after each phase. Duloxetine provided moderate benefits and intolerable side effects (hyperhidrosis). She experienced the best improvement and least side effects with the combined (CBD plus MME) phase. Noteworthy were clinically meaningful improvements in CIPN symptoms, quality of life (QoL), and perceived physical function, as well as improvements in pain, mobility, hand/finger dexterity, and upper and lower body strength. CBD and MME altered gut microbiota, showing enrichment of genera that produce short-chain fatty acids. CBD and MME may improve CIPN symptoms, QoL, and physical function through anti-inflammatory and neuroprotective effects in cancer survivors suffering from long-standing CIPN.

Details

Title
Impact of Cannabidiol and Exercise on Clinical Outcomes and Gut Microbiota for Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors: A Case Report
Author
Vigano, MariaLuisa 1 ; Kubal, Sarah 2 ; Lu, Yao 3 ; Habib, Sarah 2 ; Samarani, Suzanne 4 ; Cama, Georgina 2 ; Viau, Charles 3 ; Farzin, Houman 5   VIAFID ORCID Logo  ; Koudieh, Nebras 5 ; Xia, Jianguo 6   VIAFID ORCID Logo  ; Ahmad, Ali 4 ; Vigano, Antonio 2 ; Costiniuk, Cecilia T 7   VIAFID ORCID Logo 

 Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3A 0G4, Canada; Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada 
 Division of Supportive and Palliative Care, McGill University Health Centre, Montreal, QC H4A 3J1, Canada 
 Institute of Parasitology, Faculty of Agricultural and Environmental Sciences, McGill University, Ste-Anne-de-Bellevue, QC H9X 3V9, Canada 
 Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada 
 Division of Palliative Care, Jewish General Hospital, Montreal, QC H3T 1E2, Canada 
 Institute of Parasitology, Faculty of Agricultural and Environmental Sciences, McGill University, Ste-Anne-de-Bellevue, QC H9X 3V9, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 0G4, Canada 
 Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3A 0G4, Canada; Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada; Division of Infectious Diseases and Chronic Viral Illness Service, Royal Victoria Hospital—Glen Site, McGill University Health Centre, Montreal, QC H4A 3J1, Canada 
First page
834
Publication year
2024
Publication date
2024
Publisher
MDPI AG
e-ISSN
14248247
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3084974505
Copyright
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.